UK private surgery drive attacked in high-profile NHS resignation:
This article was originally published in Clinica
Executive Summary
The head of an NHS trust has resigned publicly in protest at the way the private sector has been granted priority access to a high-volume, low-cost surgery market, to the detriment of the more complex, high-investment activities demanded of NHS hospitals. While there is a place for private providers, their increasing use is threatening the very operability of the NHS and "pushing it to the point of no return", said Debbie Abrahams, chair of Rochdale Primary Care Trust. She voiced her criticism of the increasingly destabilising privatisation of the NHS during a march (Manchester, June 24) to protest at the service and staffing cuts linked to the current financial crisis. The issue of service privatisation and "US-style supermarket attitudes to health" are at the top of the agenda of the British Medical Association's annual conference, which begins today in Belfast (see related story).
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.